Semaglutide Insurance Coverage

UnitedHealthcare covers Wegovy for members with BMI >= 30 or >= 27 with comorbidities, typically requiring prior authorization and documentation of prior weight management attempts. Cigna has expanded coverage in 2025-2026, with similar BMI criteria. Aetna covers Wegovy under most commercial plans with prior auth. Blue Cross Blue Shield coverage varies significantly by state and plan.

Employer-sponsored plans make independent coverage decisions, so two people with the same insurer may have different coverage based on their employer's benefit design. Self-funded employers (common among large companies) have increasingly added anti-obesity medication coverage as the ROI data on reduced diabetes, cardiovascular events, and orthopedic procedures has become compelling.

Medicare Part D currently does not cover medications prescribed solely for weight loss, including Wegovy. This is a statutory exclusion that requires Congressional action to change. The bipartisan TREAT Act aims to remove this exclusion, and its passage would significantly expand semaglutide access for seniors.

Medicare does cover Ozempic when prescribed for type 2 diabetes. Some patients with both diabetes and obesity may be prescribed Ozempic for diabetes with weight loss as a secondary benefit, though this does not provide the higher Wegovy doses.

Medicaid coverage varies by state. Some states have added anti-obesity medication coverage, while others maintain exclusions. Check your state's Medicaid formulary for current coverage status.

Prior authorization is required by nearly all insurers for semaglutide. To improve your chances of approval: ensure your medical records document a BMI >= 30 (or >= 27 with at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidemia, or sleep apnea). Document previous weight management attempts including diet, exercise, and any prior medications or programs.

Your prescribing provider should submit detailed clinical notes explaining medical necessity. Include relevant lab work (A1C, lipid panel, liver enzymes), current medications for weight-related conditions, and the impact of obesity on your health and quality of life. The more thorough the documentation, the higher the approval rate.

If your prior authorization is denied, you have the right to appeal. Request the written denial letter, which must specify the reason for denial. Common denial reasons include: not meeting BMI criteria, insufficient documentation of prior attempts, step therapy requirements (must try other treatments first), or the medication not being on formulary.

File a Level 1 internal appeal with additional documentation addressing the specific denial reason. Include a letter of medical necessity from your provider, updated clinical records, and peer-reviewed literature supporting semaglutide for your condition. If the internal appeal is denied, you can file an external appeal with an independent review organization. External appeals overturn approximately 40-50% of internal denials.